Loviride

From Wikipedia, the free encyclopedia

Loviride
Systematic (IUPAC) name
2-[(2-Acetyl-5-methylphenyl)amino]-2-(2,6-dichlorophenyl)acetamide
Identifiers
CAS number  ?
ATC code  ?
PubChem 3963
Chemical data
Formula C17H16Cl2N2O2 
Mol. mass 351.227 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes  ?

Loviride (also called Loveride) was an antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is an NNRTI that entered phase III clinical trials in the late 1990s but failed to gain marketing approval because of poor potency. It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR and AVANTI), because in those trials Loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance to all NNRTI's.

[edit] Synonyms

  • Loveride
  • R089439

[edit] External links

v • d • e
Antivirals used against HIV (HAART) (primarily J05)
Nucleoside & Nucleotide
Reverse Transcriptase
Inhibitors (NRTI)
Non-Nucleoside
Reverse Transcriptase
Inhibitors (NNRTI)
Efavirenz° • Nevirapine • Etravirine • Rilpivirine† • Loviride‡ • Delavirdine‡
Protease Inhibitors (PI)
Entry/fusion inhibitors
Integrase inhibitors
Maturation inhibitors
Bevirimat† • Vivecon™†
Combined formulations
Other &
experimental agents
°DHHS preferred first-line agent. †Undergoing clinical trials, not FDA approved. ‡Formerly or rarely used agent.


Pills  This antimicrobial-related article is a stub. You can help Wikipedia by expanding it.